Granulocyte transfusions. Time for a second look.
Among the available therapies to support neutropenic patients with infection, granulocyte transfusions have generated considerable controversy. Plagued by the inconvenience of harvesting cells, infusion-associated toxicity, and marginal efficacy, granulocyte transfusions, once in vogue in the 1980s, had been relegated to a secondary role. Several recent developments, however, have given new impetus to re-evaluating the role of granulocyte transfusions. The two most notable reasons include the ability to increase the number of circulating granulocytes in the donor by treatment with one or two doses of recombinant hematopoietic growth factors, such as granulocyte- and granulocyte-macrophage colony stimulating factor, and improvements in the efficiency of the collection process. Armed with these advances, it is an appropriate time to review the existing data and consider studies designed to determine the appropriate role of granulocyte transfusions in neutropenic hosts.
Chanock
S J
SJ
National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Gorlin
J B
JB
D016207:Cytokines / Q000494:pharmacology; D006098:Granulocytes / Q000637:transplantation*; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D006801:Humans; D007239:Infections / Q000150:complications / Q000628:therapy; D007937:Leukapheresis / Q000592:standards; D017708:Leukocyte Transfusion / Q000706:statistics & numerical data; D009503:Neutropenia / Q000150:complications / Q000628:therapy*
D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors